Contents
Editor’s Letter
Latest features in GaBI Journal, 2017, Issue 3
Commentary
Patent expiry and costs for anticancer medicines for clinical use
Original Research
A survey of Australian prescribers’ views on the naming and substitution of biologicals
Review Article
Biosimilars in Italy: what do real-world data reveal?
Special Report
Physician associations comment on FDA’s interchangeability guidance
Meeting Report
Pharmacovigilance, traceability and building trust in biosimilar medicines
Value-added medicines: how repurposed medicines bring value to patients and pharmacists